All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How can chromosomal and mutation abnormalities in chronic MPN inform clinical decision making?

Dec 27, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Alessandro Vannucchi, University of Florence, Florence, IT. We asked, How can chromosomal and mutation abnormalities in chronic myeloproliferative neoplasms (MPN) inform clinical decision making?

How can chromosomal and mutation abnormalities in chronic MPN inform clinical decision making?

Vannucchi opens by outlining the history of the discovery of gene mutations within MPN that have led to the development of the three classes of driver mutations: JAK2, MPL, and CALR. Vannucchi continues by discussing the recent developments and improvements in scoring criteria methods and considers the applications of these two factors in combination for patients with primary myelofibrosis. Vannucchi concludes that with improved scoring systems and the addition of novel molecular values, this can allow for patients to be better stratified within risk categories.